KVUE Stock Chart & Stats
$329.00
$0.00(0.00%)
At close: 4:00 PM EDT
$329.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$259.01 - $450.00
Previous CloseN/A
Volume0.00
Average Volume (3M)76.00
Market Cap
$639.85B
Enterprise Value$41.40K
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$8.48B
Price to Earnings (P/E)22.6
Beta-0.16
Next Earnings
Nov 11, 2026EPS Estimate
5.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding1,920,008,700
10 Day Avg. Volume29
30 Day Avg. Volume76
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.06
Price to Sales (P/S)2.18
P/FCF Ratio19.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$334.41Price Target Upside1.65% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)20.77
Revenue Forecast (FY)$271.34B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Improved EBITSustained gross margins near 55–58% and improved EBIT margin indicate durable brand pricing power and manufacturing scale. This margin strength supports long-term reinvestment in innovation and marketing, cushions input-cost swings, and underpins cash generation over months.
Diversified Product Portfolio And Stable RevenueA broad portfolio across OTC, skincare, and essential health reduces concentration risk and smooths seasonal or category-specific shocks. Multi-channel distribution (retail, pharmacy, e-commerce) and ~stable ~$15B revenue provide structural resilience and predictability for 2–6 month planning horizons.
Strategic Transformation And Planned CombinationA planned combination with Kimberly‑Clark represents a structural strategic move that could deliver scale, cost synergies, and broader distribution. If executed, this alters long-term competitive positioning and can improve operating leverage and resource access beyond near-term results.
Bears Say
Weakened Cash GenerationSharp declines in operating and free cash flow reduce financial flexibility to fund R&D, marketing, dividends or deleveraging. Over a multi-month horizon, weaker cash conversion raises the risk of constrained capital allocation and limits the company's ability to absorb shocks or fund strategic initiatives.
Moderate-to-elevated LeverageDebt near 0.8x equity leaves less buffer versus lower-debt peers. Combined with weaker cash flow, this reduces balance-sheet flexibility for M&A or cyclical downturns and increases interest/ refinancing sensitivity, making capital structure management a medium-term operational constraint.
Earnings Volatility And Weaker Below-the-line ConversionMaterial decline in net income despite stable revenue points to inconsistent cost control, nonoperating items, or tax/interest pressures. Persistent earnings volatility undermines forecasting, complicates capital allocation and dividend planning, and raises execution risk over the coming quarters.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $259.01 and its highest was $450.00 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $639.85B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 96 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Aug 06, 2026. The company reported $5.333 earnings per share for the quarter, missing the consensus estimate of $5.488 by -$0.155.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. does not currently pay dividends.
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 5.06.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,920,008,700 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $5.333 in its last earnings report, missing expectations of $5.488. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in MX:KVUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kenvue, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$334.41 (1.65% Upside)
$334.41 (1.65% Upside)
Blogger Sentiment
Bullish
MX:KVUE Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $12.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.33%
12-Months-Change
Fundamentals
Return on Equity
4.57%
Trailing 12-Months
Asset Growth
2.27%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.17% Self Care
27.20% Skin Health and Beauty
30.63% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
$334.41
▲(1.65% Upside)